VANCOUVER, British Columbia--(BUSINESS WIRE)--Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today the publication of new preclinical data from additional confirmatory animal studies showing that Allon’s product candidate AL-108 significantly reduces the accumulation of amyloid peptide and the hyperphosphorylation of tau protein in the brain, two pathological hallmarks of Alzheimer’s.
